Clinical Trial Update: Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sintilimab with docetaxel for non-driver gene mutation metastatic non-small cell lung cancer after standard chemotherapy failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Sintilimab (sintilimab)

Snippet

Sponsor: Yongchang Zhang | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED